Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) had its price objective raised by UBS Group from $21.00 to $22.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.
Separately, William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.
Check Out Our Latest Analysis on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 2.7 %
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Read More
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Steel Stocks Soaring After Tariff Announcements
- How Investors Can Find the Best Cheap Dividend Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
